10-K: America Great Health Files Annual Report Amidst Going Concern Doubts

America Great Health (AAGH) has filed its annual report for the fiscal year ended June 30, 2025, detailing operational results, financial condition, and forward-looking statements, while acknowledging substantial doubt about its ability to continue as a going concern.

Summary

• America Great Health (AAGH) has filed its Form 10-K for the fiscal year ended June 30, 2025.
• The company reported sales of $391,743 for the fiscal year 2025, an increase from $294,670 in 2024, attributed to new product launches.
• Gross profit increased to $339,121 in 2025 from $169,750 in 2024.
• Operating expenses decreased to $722,056 in 2025 from $952,450 in 2024, due to reductions in selling, office, professional, reserve, and stock compensation expenses.
• The net loss for fiscal year 2025 was $721,242, a significant improvement from $1,226,362 in 2024.
• Despite the improved net loss, the company has a shareholders deficit of $5,743,827 as of June 30, 2025, and used $332,862 in cash for operating activities.
• These factors raise substantial doubt about the company's ability to continue as a going concern.
• The company is seeking additional capital to achieve profitable operations.
• The independent auditor issued a disclaimer of opinion on the financial statements for the year ended June 30, 2025, citing insufficient supporting documentation for expenses, lack of appropriate analysis over the consolidation of Purecell Group, and inability to obtain sufficient audit evidence regarding opening balances.
• A similar disclaimer of opinion was issued for the June 30, 2024 financial statements.
• The company's common stock is listed on the OTC Bulletin Board under the symbol AAGH and traded at $0.0002 per share as of June 30, 2025.
• The company has not paid any dividends and does not anticipate paying them in the foreseeable future.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the significant going concern doubts, the disclaimer of opinion from the auditor, and the extremely low stock price, despite some improvements in sales and reduced net loss.

Positives

• Sales increased by approximately 33% to $391,743 in fiscal year 2025 compared to $294,670 in fiscal year 2024, driven by new product launches.
• Gross profit improved significantly, rising to $339,121 in 2025 from $169,750 in 2024.
• Net loss decreased substantially to $721,242 in 2025 from $1,226,362 in 2024.
• Operating expenses were reduced by approximately 24% to $722,056 in 2025 from $952,450 in 2024.

Negatives

• The company has a shareholders deficit of $5,743,827 as of June 30, 2025.
• The company used $332,862 in cash for operating activities during fiscal year 2025.
• The independent auditor issued a disclaimer of opinion on the financial statements for both fiscal years 2025 and 2024 due to significant audit limitations.
• The company acknowledges substantial doubt about its ability to continue as a going concern.
• The stock price was extremely low at $0.0002 per share as of June 30, 2025.
• The company has not paid any dividends and does not plan to in the foreseeable future.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring losses, shareholder deficit, and negative cash flow from operations.
• The company is dependent on its majority shareholder for future working capital.
• The independent auditor's disclaimer of opinion indicates significant issues with financial record-keeping and audit evidence, posing a risk to the reliability of reported financial information.
• The company's stock is subject to penny stock rules, which may restrict trading and liquidity.
• The company has identified material weaknesses in its internal control over financial reporting, including a lack of segregation of duties and insufficient Board of Directors representation, due to inadequate staffing and working capital.
• The company's operations and financial reporting are subject to risks associated with its international subsidiaries, particularly in China.
• The termination of the Cooperation Agreement with Purecell Group in November 2025 signifies a potential unwinding of a significant past investment and strategic relationship.

Future Outlook

The company is focused on investing in innovative technologies within the healthcare ecosystem, including R&D for protein and peptide small molecular drugs, AI-driven diagnostics and medical devices, cell therapy, regenerative medicine, and supplements manufacturing and sales. However, the company's ability to continue as a going concern is dependent on securing additional capital and achieving profitable operations. Future working capital needs are expected to be met by the current majority shareholder.

Management Comments

• Management acknowledges that the company has incurred recurring net losses and has a shareholders deficit, creating substantial doubt about its ability to continue as a going concern.
• Management has concluded that the company's internal control over financial reporting was not effective as of June 30, 2025, primarily due to a lack of segregation of incompatible duties and insufficient Board of Directors representation.
• Management intends to hire additional accounting personnel to assist with financial reporting as soon as finances allow.
• The company has not adopted a code of ethics but intends to do so in the near future.
• The Board of Directors believes that obtaining an audit committee financial expert is not economically rational at this time due to costs and the limited scope of operations.

Industry Context

StockSavvy.ai notes that America Great Health operates in the health and biotechnology sector, a field characterized by significant R&D investment, regulatory hurdles, and a long path to commercialization. The company's focus on areas like peptide drugs, cell therapy, and regenerative medicine aligns with emerging trends, but its current financial precariousness and auditor's disclaimer of opinion present significant challenges.

Comparison to Industry Standards

• The company's sales of $391,743 for the fiscal year 2025 are significantly lower than industry benchmarks for established healthcare or biotechnology firms, which often report revenues in the millions or billions.
• The net loss of $721,242, while reduced from the prior year, indicates a lack of profitability that is not sustainable for long-term industry players.
• The company's market capitalization, implied by its stock price of $0.0002 and over 21 billion shares outstanding, is extremely low, placing it far below typical industry valuations.
• The disclaimer of opinion from the auditor is a critical deviation from industry standards, where clean audit opinions are expected for publicly traded companies.
• The company's reliance on related party advances for working capital is a common characteristic of early-stage or distressed companies, contrasting with more mature companies that access capital markets or generate sufficient operating cash flow.

Corporate Governance

Legal Proceedings

• No legal proceedings are threatened or pending against the company or any of its officers or directors.

Related Party Transactions

• During the year ended June 30, 2025, the company's current majority shareholder advanced $635,044 as working capital, and the company repaid $493,601 to the shareholder.
• As of June 30, 2025, the company owed its current majority shareholder and other related parties $1,251,639, which are non-interest bearing and due on demand.

Stakeholder Impact

• Shareholders: The extremely low stock price and going concern doubts pose a significant risk to shareholder value. The lack of dividends also limits immediate returns.
• Creditors: The company's financial instability and going concern issues may impact its ability to meet its obligations, increasing risk for creditors.
• Employees: With only five full-time employees, the impact is limited, but job security could be affected by the company's financial situation.
• Suppliers: The company's financial health could affect its ability to pay suppliers on time, as indicated by the concentration of purchases from three major vendors.

Next Steps

• The company intends to hire additional accounting personnel as soon as finances allow.
• The company plans to continue seeking additional capital to achieve profitable operations.
• The company will continue to develop its focus on protein and peptide small molecular drugs R&D, diagnostic and medical devices with AI cloud computing, cell therapy, and regenerative medicine.
• The company and Purecell have agreed to terminate their Cooperation Agreement, with directors' resignations by December 31, 2025, indicating a strategic shift away from this partnership.

Key Dates

Recommendation

The company's filing reveals severe financial distress, including substantial doubt about its going concern status, a disclaimer of opinion from its auditor, a significant shareholders deficit, and an extremely low stock price. Despite a reduction in net loss and an increase in sales, these fundamental issues, coupled with material weaknesses in internal controls, make the stock a high-risk investment. The lack of clear profitability and reliance on shareholder advances for survival suggest a sell recommendation.

Keywords

America Great Health, Form 10-K, Annual Report, Financial Statements, Going Concern, Net Loss, Sales, Operating Expenses, Shareholders Deficit, Healthcare, Biotechnology, SEC Filing, AAGH